- Annovis Bio ( NYSE: ANVS ) announced Wednesday the EU approval to bring additional 48 trial sites for its Phase 3 study for lead candidate buntanetap in the treatment of Parkinson's disease ("PD").
- With 50 clinical trial sites open in the U.S., the clinical-stage biotech is currently enrolling patients for the randomized study, which tests buntanetap 10mg or 20mg vs. placebo in addition to standard of care for six months.
- "We are pleased to significantly expand our geographic reach with the addition of these EU sites that gives us the ability to efficiently enroll European patients in our study," Chief Executive of Annovis ( ANVS ) Maria Maccecchini remarked.
- The company intends to enroll early PD patients in these additional trial sites, spread across countries such as Italy, Spain, Hungary, Poland, and Germany. An interim readout is expected in Q2 2023 if there is a sufficient number of patients who have received two months of therapy.
- Seeking Alpha contributor Terry Chrisomalis issued a Strong Buy rating on Annovis ( ANVS ) last year, citing the potential of buntanetap in PD.
For further details see:
Annovis wins EU nod to expand late-stage trial for Parkinson's candidate